CoChat

MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges

Open access

The DOI matches its Crossref record; 232 of the 253 references it cites were found in a registry or an index; 117 of the 241 sources its claims cite were checked for support.

Abstract

Mitogen-activated protein kinase (MAPK) pathways represent ubiquitous cellular signal transduction pathways that regulate all aspects of life and are frequently altered in disease. Once activated through phosphorylation, these MAPKs in turn phosphorylate and activate transcription factors present either in the cytoplasm or in the nucleus, leading to the expression of target genes and, as a consequence, they elicit various biological responses. The aim of this work is to provide a comprehensive review focusing on the roles of MAPK signaling pathways in ocular pathophysiology and the potential to influence these for the treatment of eye diseases. We summarize the current knowledge of identified MAPK-targeting compounds in the context of ocular diseases such as macular degeneration, cataract, glaucoma and keratopathy, but also in rare ocular diseases where the cell differentiation, proliferation or migration are defective. Potential therapeutic interventions are also discussed. Additionally, we discuss challenges in overcoming the reported eye toxicity of some MAPK inhibitors.

Overview

CoChat Summary

TL;DR

This review summarizes MAPK signaling in ocular development and disease, covering AMD, diabetic retinopathy, retinal dystrophies, glaucoma, corneal wound healing, dry eye, keratoconus, aniridia, uveitis, and cataract. It highlights potential MAPK-targeting drugs but cautions that systemic MEK/B-Raf inhibition can cause ocular adverse effects such as MEKAR and uveitis.

Key findings

  • MAPK subfamilies ERK1/2, JNK1/2/3, p38, and ERK5 are implicated across ocular pathophysiology; ERK generally promotes proliferation/differentiation, while p38/JNK mediate stress, inflammation, apoptosis, and wound healing.
  • In AMD, DR, RD, glaucoma, and corneal/aniridia models, specific MAPK inhibition or modulation showed positive effects in vitro and in animals; e.g., MEK inhibitor PD0325901 partially rescued aniridia phenotype in an AAK mouse model, and Duloxetine/Ritanserin restored PAX6 via MEK/ERK inhibition.
  • MEK inhibitor–associated retinopathy (MEKAR) features serous detachments of neurosensory retina, commonly bilateral (92%) and multifocal (77%, median 6 foci), with fluid between RPE and interdigitation zone; usually mild/self-limited, but binimetinib effects can fluctuate daily and sometimes lead to subclinical retinal thinning.
  • Systemic MAPK inhibitor adverse effects include uveitis with B-Raf inhibitors and central serous chorioretinopathy/MEKAR with MEK inhibitors; Duloxetine eye toxicity included blurred vision (6.7%), uncommon diplopia/dry eye/mydriasis/visual impairment (<1%), and rare glaucoma (<0.1%).

Methods

  • Narrative review of published literature on MAPK pathways in ocular pathophysiology and MAPK-targeting compounds; no primary experimental data.
  • Evidence synthesized includes in vitro cell studies, animal models, human clinical reports, and bioinformatic/GWAS analyses across retinal, corneal, uveal, and lens diseases.
  • Main analysis is qualitative synthesis, with tables summarizing MAPK components and reported adverse effects of specific MAPK inhibitors; no systematic search strategy or meta-analysis is described.

Limitations

  • Stated: many conclusions rely on in vitro and animal studies; for cataract, the paper notes insufficient mechanistic in vivo data, and for keratoconus it calls for more targeted research.
  • Stated: long-term effects of MAPK inhibitors in populations with specific eye disease are unknown, and adverse effects have been observed mainly with systemic administration and sustained therapeutic schemes; topical or time-limited delivery remains to be investigated.
  • Evident from the text: this is a narrative review without a described systematic search or quantitative synthesis, so selection and interpretation biases cannot be excluded.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cells12040617

Cites

232 of 232 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Simplified schematic summary of the main MAPK signaling pathways.
Figure 1 Simplified schematic summary of the main MAPK signaling pathways.CC BY · PubMed Central
Figure 2 Schematic overview of developmental events during mammalian eye development, and germ layer origin of structures in the eye. (A) The optic vesicle, derived from the neuroepithelium of ectodermal lineage, approaches the surface ectoderm where the lens placode (blue cells) forms at the area of proximity between the layers. (B) The optic vesicle forms the optic cup, by the concurrent invagination of both the lens placode, forming the lens pit, and the proximal layer of the optic vesicle to the surface ectoderm, forming the presumptive neural retina (red cells). (C) The lens pit closes up onto itself forming the lens vesicle, with the cells from the central part of the lens pit (blue cells) directed posteriorly, and the cells from the lens pit periphery (yellow cells) directed anteriorly. The optic cup continues to invaginate. (D) The invaginated (inner) layer of the optic cup differentiates into the neural retina (red cells), while the outer layer forms the retinal pigment epithelium, RPE (orange cells). Cells in the posterior surface of the lens vesicle elongate towards the opposite pole, forming the lens fibers and filling the central volume of the lens, while the cells on the anterior side form the lens anterior epithelium. The surface ectoderm closes after the lens vesicle detaches, and the now continuous surface ectoderm forms the cornea.
Figure 2 Schematic overview of developmental events during mammalian eye development, and germ layer origin of structures in the eye. (A) The optic vesicle, derived from the neuroepithelium of ectodermal lineage, approaches the surface ectoderm where the lens placode (blue cells) forms at the area of proximity between the layers. (B) The optic vesicle forms the optic cup, by the concurrent invagination of both the lens placode, forming the lens pit, and the proximal layer of the optic vesicle to the surface ectoderm, forming the presumptive neural retina (red cells). (C) The lens pit closes up onto itself forming the lens vesicle, with the cells from the central part of the lens pit (blue cells) directed posteriorly, and the cells from the lens pit periphery (yellow cells) directed anteriorly. The optic cup continues to invaginate. (D) The invaginated (inner) layer of the optic cup differentiates into the neural retina (red cells), while the outer layer forms the retinal pigment epithelium, RPE (orange cells). Cells in the posterior surface of the lens vesicle elongate towards the opposite pole, forming the lens fibers and filling the central volume of the lens, while the cells on the anterior side form the lens anterior epithelium. The surface ectoderm closes after the lens vesicle detaches, and the now continuous surface ectoderm forms the cornea.CC BY · PubMed Central
Figure 3 Graphical overview of eye structures and conditions for which MAPK interactions have been reported.
Figure 3 Graphical overview of eye structures and conditions for which MAPK interactions have been reported.CC BY · PubMed Central

Verification

Claims the paper makes

108 Valid · 5 Not valid · 97 Not checked · 15 Own results and interpretations

129 more claims · 60 with their cited sources checked

Create a free account to see all 225 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 73

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

3 of 3

Citations

Cites

3 retracted

Show all 232 references

Research works printed but not linked: 1

  1. Ryan, S.J., Sadda, S.R., Hinton, D.R., Schachat, A.P., Sadda, S.R., Wilkinson, C.P., Wiedemann, P., and Schachat, A.P. (2013). Retina, W.B. Saunders. [5th ed.].

Cited by

Metadata

Authors
Moustardas, P., Aberdam, D., & Lagali, N.
Affiliations
  • Linköping University (SE)
  • Inserm (FR)
Corresponding author
  • Moustardas, Petros
  • Aberdam, Daniel
  • Lagali, Neil
Venue
Cells
Publisher
MDPI AG
Published
2023-02-14
Volume
12
Issue
4
Pages
617
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4320919783
Cited by
63
References
253
Citations by year
2026: 21 · 2025: 26 · 2024: 10 · 2023: 7
FWCI
13.62
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • DiVA (Linkoping University) (submittedVersion, other-oa)
  • HAL (Le Centre pour la Communication Scientifique Directe) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • EJP-RD (EJPRD20-135, 2020-00798, CA-18116)
  • AAK-INSIGHT (EJPRD20-135, 2020-00798, CA-18116)
  • Swedish Research Council (EJPRD20-135, 2020-00798, CA-18116)
  • European Union Cooperation on Science and Technology COST Action (EJPRD20-135, 2020-00798, CA-18116)
  • ANIRIDIA-NET (EJPRD20-135, 2020-00798, CA-18116)
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
MAPK signaling, eye diseases, macular degeneration, cataract, glaucoma, corneal disease, MAPK inhibitors, ocular toxicity
MeSH terms
Phosphorylation, Signal Transduction, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, p38 Mitogen-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.